专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2001260696B2 Agents for proliferating pancreatic beta-cells of the islets of langerhans, agents for suppressing apoptosis of said cells, and screening of candidate compounds for these agents 未知
公开(公告)号：AU2001260696B2
公开(公告)日：2005-04-14
申请号：AU2001260696
申请日：2001-06-01
申请人： OKAMOTO HIROSHI
发明人： OKAMOTO HIROSHI
IPC分类号： A61P3/10 , A61P43/00 , C07K14/47 , C07K14/475 , G01N33/50 , A61K038/20 , C12N005/06 , C12N015/12 , C12Q001/02 , G01N033/50 , G01N033/15 , A61P003/10 , A61P043/00 , A61K031/165 , A61K031/455 , A61K045/00 , A61K048/00 , A61K038/22 , A61K031/573
摘要： The present invention provides agents for proliferating pancreatic beta -cells of Langerhans' islets, agents for suppressing apoptosis of the cells , and methods of screening for candidate compounds for these agents. The combined use of an inflammatory mediator IL-6 and glucocorticoid remarkably induces the expression of Reg gene in beta cells and thus promotes proliferation of beta cells. HGF suppresses apoptosis induced by Reg protein and IL-6 and glucocorticoid induce intracellular expression of HGF gene. PARP inhibitors such as nicotinamide and 3-aminobenzamide further enhance the induction of the expression of these genes. Moreover, based on the analysis of the expression induction mechanism using the promoter regions of Reg gene and HGF gene, methods of efficiently screening for candidate compounds for these gene expression inducers have been developed.

2. 发明专利

AU2002228435B2 Graft rejection inhibitors 未知
公开(公告)号：AU2002228435B2
公开(公告)日：2005-03-10
申请号：AU2002228435
申请日：2002-02-05
申请人： JAPAN TOBACCO INC
发明人： SUZUKI SEIICHI , ISOBE MITSUAKI
IPC分类号： A61K38/02 , A61K31/7105 , A61K31/711 , A61K38/00 , A61K39/395 , A61K45/00 , A61P37/06 , C07K16/28 , A61K045/00 , A61K031/573 , A61K038/13 , A61K031/7056 , A61K031/436 , A61K031/365 , A61K031/16 , A61K038/02 , A61K039/395 , A61K031/711 , A61K031/7105 , A61P037/06 , A61K031/52
摘要： It was found that antibodies against AILIM (also known as ICOS and 8F4) and AILIM-Ig have significant therapeutic effects towards the suppression and prevention of graft rejection. Graft rejection is a serious problem associated with tissue or organ transplantation (allotransplantation or xenotransplantation), performed to treat various organ failures (liver, heart, lung, kidney, pancreas, etc.) .

3. 发明申请

US20040208833A1 Novel fluticasone formulations 审中-公开
标题翻译：新型氟替卡松配方
公开(公告)号：US20040208833A1
公开(公告)日：2004-10-21
申请号：US10768194
申请日：2004-02-02
申请人： Elan Pharma International Ltd.
发明人： Douglas Hovey , Tuula Ryde , H. William Bosch
IPC分类号： A61L009/04 , A61K009/14 , A61K031/573
CPC分类号： A61K9/0073 , A61K9/145 , A61K9/146
摘要： The present invention is directed to fluticasone compositions comprising fluticasone and at least one surface stabilizer. The fluticasone particles of the composition preferably have an effective average particle size of less than about 2000 nm.
摘要翻译：本发明涉及包含氟替卡松和至少一种表面稳定剂的氟替卡松组合物。组合物的氟替卡松颗粒优选具有小于约2000nm的有效平均粒度。

4. 发明申请

US20040180870A1 Aqueous solvent for corticosteroids 审中-公开
标题翻译：皮质类固醇水溶剂
公开(公告)号：US20040180870A1
公开(公告)日：2004-09-16
申请号：US10809221
申请日：2004-03-25
发明人： Calvin Hanna
IPC分类号： A61K031/573
CPC分类号： A61K47/14 , A61K9/0014 , A61K31/56 , A61K47/10 , A61K47/44 , Y10S514/952 , Y10S514/97 , Y10S514/973 , Y10S514/975
摘要： A solvent comprising a combination of water and organic solvent(s) capable of dissolving a therapeutically effective amount of medicament(s) not readily soluble in aqueous solvents, said organic solvents including alcohol and glycol, and said medicaments including hydrocortisone.
摘要翻译：一种包含能够溶解治疗有效量的不易溶于水溶剂的药物的水和有机溶剂的组合的溶剂，所述有机溶剂包括醇和二醇，所述药物包括氢化可的松。

5. 发明申请

US20040180869A1 New glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility 失效
标题翻译：新型糖皮质激素受体拮抗剂用于预防和治疗糖皮质激素介导的性腺机能减退症，性功能障碍和/或不育症
公开(公告)号：US20040180869A1
公开(公告)日：2004-09-16
申请号：US10735487
申请日：2003-12-12
发明人： Ulrich Bothe , Gerd Schubert , Guenter Kaufmann , Lothar Sobek , Vladimir Patchev , Alexander Hillisch
IPC分类号： A61K031/573
CPC分类号： A61K31/00 , A61K31/567 , A61K31/573 , C07J1/00
摘要： The present invention relates to novel glucocorticoid receptor antagonists for producing a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility. For purposes of the present invention, by nullglucocorticoid receptor antagonistsnull are meant drugs capable of competitively inhibiting the effect of glucocorticoids as a result of better and more selective binding to glucocorticoid receptors The compounds according to the invention or used according to the invention are characterized in that they are significantly more dissociated, namely they bind well to the glucocorticoid receptor and act on the progesterone receptor only to aminor degree compared to 11null-(4-dimethylamino)phenyl-17null-hydroxy-17null-propyn-1-yl-estra-4,9-dien-3-one (RU 38486), a substance of very high activity but low selectivity.
摘要翻译：本发明涉及用于生产用于预防和治疗糖皮质激素介导的性腺机能减退症，性功能障碍和/或不育症的药物的新型糖皮质激素受体拮抗剂。为了本发明的目的，“糖皮质激素受体拮抗剂”是指由于更好和更选择性地结合糖皮质激素受体而能够竞争性地抑制糖皮质激素作用的药物。本发明化合物或根据本发明使用的化合物的特征在于因为它们明显更多地解离，即它们与糖皮质激素受体很好地结合，并且与11beta-（4-二甲基氨基）苯基-17β-羟基-17α-丙炔-1-基 - 雌二醇相比，仅在孕酮受体上作用于氨基酸 -4,9-二烯-3-酮（RU 38486），其活性非常高但选择性低。

6. 发明申请

US20040167109A1 Formulations of glucocorticoids to treat pathologic ocular angiogenesis 审中-公开
标题翻译：糖皮质激素治疗病理性眼血管发生的制剂
公开(公告)号：US20040167109A1
公开(公告)日：2004-08-26
申请号：US10772963
申请日：2004-02-05
发明人： David P. Bingaman , Abbot F. Clark , Rajni Jani , Stella M. Robertson
IPC分类号： A61K031/58 , A61K031/573
CPC分类号： A61K31/58 , A61K31/573 , A61K2300/00
摘要： Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema.
摘要翻译：糖皮质激素单独配制与醋酸艾司他丁配方可用于预防和治疗病理性眼血管生成及相关性水肿。

7. 发明申请

US20040132703A1 Methods for treating migraine 有权
标题翻译：偏头痛治疗方法
公开(公告)号：US20040132703A1
公开(公告)日：2004-07-08
申请号：US10703069
申请日：2003-11-05
申请人： Corcept Therapeutics, Inc.
发明人： Joseph K. Belanoff
IPC分类号： A61K031/573
CPC分类号： A61K31/59 , A61K31/00 , A61K31/56 , A61K31/573
摘要： This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating migraine in a subject.
摘要翻译：本发明涉及能够抑制糖皮质激素受体的生物学作用的药剂可用于治疗受试者偏头痛的方法。

8. 发明申请

US20040121014A1 Method for treating and/or preventing retinal diseases with sustained release corticosteroids 审中-公开
标题翻译：用持续释放的皮质类固醇治疗和/或预防视网膜疾病的方法
公开(公告)号：US20040121014A1
公开(公告)日：2004-06-24
申请号：US10714677
申请日：2003-11-14
申请人： Control Delivery Systems, Inc.
发明人： Hong Guo , Paul Ashton
IPC分类号： A61K031/573 , A61K009/24
CPC分类号： A61K9/0051 , A61K31/573
摘要： The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
摘要翻译：本发明涉及向眼后段施用皮质类固醇的方法。在该方法中，植入持续释放装置以将皮质类固醇递送至眼睛。在皮质类固醇释放期间，皮质类固醇水溶液的浓度仍然低于玻璃质皮质类固醇浓度。

9. 发明申请

US20040121009A1 Method of modifying the release profile of sustained release compositions 审中-公开
标题翻译：改变持续释放组合物释放曲线的方法
公开(公告)号：US20040121009A1
公开(公告)日：2004-06-24
申请号：US10681571
申请日：2003-10-08
申请人： Alkermes Controlled Therapeutics, Inc.
发明人： James R. Dasch , M. Gary I. Riley , Paul A. Burke , Susan A. Steitz-Abadi , Stephen E. Zale
IPC分类号： A61K031/573 , A61K009/22
CPC分类号： A61K9/0024 , A61K9/1647 , A61K9/1694 , A61K31/573 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a method for the sustained release in vivo of a biologically active labile agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active labile agent incorporated therein, and a corticosteroid wherein the labile is released for a period of at least about two weeks. It is understood that the corticosteroid is present in an amount sufficient to modify the release profile of the biologically active labile agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.
摘要翻译：本发明涉及一种用于生物活性不稳定试剂体内持续释放的方法，其包括向需要治疗的受试者施用有效量的持续释放组合物，其包含其中掺入生物活性不稳定剂的生物相容性聚合物，和一种皮质类固醇，其中不稳定性释放至少约两周。应当理解，皮质类固醇以足以改变生物活性不稳定剂从持续释放组合物的释放曲线的量存在。还公开了适用于本发明方法的药物组合物。

10. 发明申请

US20040097474A1 Use of an anti-allergy agent and a steroid to treat nasal conditions 审中-公开
标题翻译：使用抗过敏剂和类固醇治疗鼻腔疾病
公开(公告)号：US20040097474A1
公开(公告)日：2004-05-20
申请号：US10706759
申请日：2003-11-12
申请人： Alcon, Inc.
发明人： Gerald D. Cagle , G. Michael Wall , John M. Yanni , Rajni Jani , Haresh G. Bhagat
IPC分类号： A61K031/573 , A61L009/04 , A61K009/14
CPC分类号： A61K31/5513 , A61K9/0043 , A61K31/355 , A61K31/573 , A61K31/575 , A61K2300/00
摘要： Compositions and methods for treating rhinitis with certain combinations of antiallergic agents and steroids are disclosed.
摘要翻译：公开了用抗过敏剂和类固醇的某些组合治疗鼻炎的组合物和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式